Safe Harbor

The patent safe harbor under 35 U.S.C. § 271(e)(1) protects certain activities from patent infringement liability: STATUTORY TEXT: 'It shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention...solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products'; ORIGINAL PURPOSE: enacted in 1984 as part of the Hatch-Waxman Act to enable generic drug manufacturers to conduct bioequivalence testing on patented drugs before the branded patent expired; without the exemption, generic manufacturers could not begin testing until the patent expired, delaying generic entry; SCOPE EXTENDED BY COURTS: ELI LILLY AND CO. v. MEDTRONIC (S.Ct. 1990): the safe harbor covers medical devices subject to FDA approval under the Medical Device Amendments, not just drugs; the Court interpreted 'Federal law which regulates' broadly to cover all FDA-regulated products; MERCK KGAA v. INTEGRA LIFESCIENCES (S.Ct. 2005): the safe harbor extends to ALL information submitted to the FDA — not just generic drug ANDA submissions; covers preclinical research activities (animal testing, in vitro studies) that generate data that MAY be submitted to the FDA; covers research on compounds that may not ultimately be submitted (exploratory research in the drug development process); WHAT IS COVERED: clinical trials and preclinical research; bioequivalence testing; biosimilar development activities; FDA submission preparation; WHAT IS NOT COVERED: purely commercial manufacturing; stockpiling products for sale after patent expiration (Intermedics v. Guidant, Fed. Cir. 2001); activities with no reasonable connection to an FDA submission.

Merck KGaA v. Integra Lifesciences (S.Ct. 2005) is the landmark case defining the full scope of § 271(e)(1): BACKGROUND: Merck KGaA used Integra's patented RGD peptide compounds in preclinical (animal) research to evaluate potential drug candidates for angiogenesis inhibition; Merck did not submit the specific tested compounds to the FDA — it was exploratory research; Integra sued for infringement; ISSUE: does the safe harbor cover preclinical research that is part of the drug development process, even if the tested compound is not ultimately submitted to the FDA? HOLDING: YES — the safe harbor covers 'all uses of patented inventions that are reasonably related to the development and submission of any information under the FDCA'; SCOPE OF HOLDING: (1) extends to ALL FDA submissions, not just ANDA (generic drug) submissions; (2) covers preclinical activities that generate data that may be submitted to FDA; (3) does NOT require that the specific tested compound be ultimately submitted; (4) covers exploratory research that will generate information potentially submitted under the FDCA; WHAT THE EXEMPTION DOES NOT COVER: basic scientific research using a compound as a tool (beyond any regulatory submission context); commercial stockpiling of patented products before patent expiration; LIMITS ON MERCK EXPANSION: the activity must be 'reasonably related' to FDA submission; not every use of a patented invention in a lab qualifies; use as a general scientific research tool (Classen Immunotherapies, Fed. Cir. 2011) does not qualify; IMPACT: generic manufacturers, biosimilar developers, and medical device companies can conduct extensive preclinical and clinical testing on patented inventions during the patent term.

There are two distinct research exceptions in US patent law: the statutory Bolar exemption and the narrow common law experimental use exception: COMMON LAW EXPERIMENTAL USE EXCEPTION: arose from Whittemore v. Cutter (1813), where Justice Story suggested that making a patented machine 'for the purpose of philosophical experiment' did not constitute infringement; the exception has been recognized but interpreted VERY narrowly; MADEY v. DUKE UNIVERSITY (Fed. Cir. 2002): the Federal Circuit dramatically limited the common law exception; Duke University used patented free-electron lasers in its research laboratories without a license; the court held: the exception only applies to experiments 'for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry'; any use that advances the research institution's legitimate business purposes does NOT qualify; university research has commercial purposes (grant funding; reputation; faculty promotion) — therefore NOT exempt; the exception is 'very narrow and strictly limited'; PRACTICAL RESULT: universities and research institutions have essentially no common law experimental use exemption in the US; any research using a patented invention requires a license unless the Bolar exemption (§ 271(e)(1)) or another exception applies; INTERNATIONAL CONTRAST: many countries have broad research exemptions; Germany: experiments 'on' the patented subject matter to understand the invention are exempt; UK: acts done 'for experimental purposes relating to the subject matter of the invention' are exempt; Japan, Canada, Australia: similar research exemptions; US common law exception is among the narrowest in the world; IMPACT ON ACADEMIC RESEARCH: US researchers using patented tools, research materials, or methods technically infringe unless they have a license; in practice, patent holders rarely enforce against nonprofit academic research (reputational concerns; small economic value).

The Bolar exemption profoundly shapes pharmaceutical patent strategy and generic drug entry timing: HATCH-WAXMAN REGULATORY FRAMEWORK: Hatch-Waxman (Drug Price Competition and Patent Term Restoration Act of 1984) created a balanced system: Bolar exemption (§ 271(e)(1)): enabled generic testing before patent expiration; patent term restoration (§ 156): extended patent terms to compensate for FDA approval delays; this balance aimed to ensure both innovation incentives and timely generic competition; ANDA PATENT CERTIFICATION: generic manufacturers filing an ANDA (Abbreviated New Drug Application) must certify regarding the listed patents; Paragraph IV certification: the listed patent is invalid or not infringed by the generic product; filing a Paragraph IV certification = constructive infringement (a legal fiction that allows immediate litigation); 30-month stay: if the patent holder sues within 45 days of the Paragraph IV notice, a 30-month stay automatically delays FDA approval; SAFE HARBOR DURING PARA IV LITIGATION: the generic manufacturer can use the Bolar exemption to continue clinical trials and FDA submission preparation during the 30-month stay; stockpiling product for launch after patent expiration is NOT protected by the safe harbor; BIOSIMILAR (BPCIA) CONTEXT: the Biologics Price Competition and Innovation Act (BPCIA) created a similar framework for biologics; biosimilar manufacturers can conduct interchangeability studies and clinical trials under the safe harbor; complex patent dance provisions govern patent disclosure and litigation; AT-RISK LAUNCH: a generic or biosimilar manufacturer may choose to launch after FDA approval but before a patent lawsuit resolves; if the patent is later upheld, the manufacturer owes lost profits or reasonable royalty; the safe harbor only covers pre-launch activities, not commercial sales.

The safe harbor has important boundaries that patent practitioners and companies must understand: SOLELY FOR REGULATORY PURPOSES: activities must be solely (exclusively) related to FDA submission; if an activity serves both a regulatory and a commercial purpose, it may not be fully protected; courts use a reasonableness standard: would a reasonable person conclude the activity was related to generating FDA submission data?; STOCKPILING EXCLUSION: Intermedics v. Guidant (Fed. Cir. 2001): commercial stockpiling of products for post-patent-expiration launch = NOT exempt; making products in quantities exceeding what is needed for FDA submissions = infringement; timing matters: manufacturing only begins to be non-exempt when it exceeds FDA submission needs; RESEARCH TOOL EXCEPTION: patents on research tools (DNA sequences used as assay reagents; cell lines; antibodies used as screening tools) are generally NOT exempt when used as tools rather than as the subject of research; Classen Immunotherapies (Fed. Cir. 2011): activities completed prior to initiating a clinical trial for FDA submission do not necessarily qualify; VETERINARY BIOLOGICS: § 271(e)(1) covers 'veterinary biological products' — animal vaccines, diagnostic biologics, similar products regulated by USDA's APHIS (not FDA); the safe harbor extends to USDA-regulated activities as well; EXPORTS FOR FOREIGN REGULATORY ACTIVITIES: § 271(e)(1) protects activities for US FDA submissions; manufacturing in the US for submission to foreign regulatory authorities (EMA, PMDA) is NOT covered by § 271(e)(1); separate provisions (§ 271(e)(1) as applied to exports) have not fully resolved this; PATENT CLAIM SCOPE: the safe harbor only protects using patented inventions in covered activities; it does not protect copying the patent itself or obtaining trade secrets; narrow patents on specific processes (vs. the compound itself) are still infringed if the process is used in a covered activity without authorization.